Scilex Holding (SCLXW) Total Non-Current Liabilities (2020 - 2026)

Scilex Holding (SCLXW) recorded quarterly Total Non-Current Liabilities of $522.2 million in Q1 2026, down 9.43% quarter-over-quarter from $576.6 million in Q4 2025, and up 121.57% on a YoY basis from $235.7 million in Q1 2025.

Scilex Holding (SCLXW) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Scilex Holding's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $522.2 million for Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities rose 121.57% year-over-year to $522.2 million; the TTM figure through Mar 2026 stood at $522.2 million (up 121.57% YoY), while the FY2025 annual figure was $576.6 million, up 102.59% from the prior year.
  • Total Non-Current Liabilities was $522.2 million for Q1 2026 at Scilex Holding, down from $576.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $576.6 million in Q4 2025 to a low of $11.0 million in Q3 2022.
  • Historically, Total Non-Current Liabilities has averaged $237.2 million across 5 years, with a median of $272.7 million in 2023.
  • The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities sank 81.57% in 2022, then jumped 2090.64% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $49.1 million in 2022, then jumped by 455.94% to $272.7 million in 2023, then increased by 4.35% to $284.6 million in 2024, then soared by 102.59% to $576.6 million in 2025, then dropped by 9.43% to $522.2 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $522.2 million (Q1 2026), $576.6 million (Q4 2025), and $373.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -31.03 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 48.74 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 119.22 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 108.96 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 75.11 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 80.55 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 31.56 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 113.51 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 61.52 Bn
10 Scilex Holding - - 4.15 Mn 522.16 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 522.16 Mn
Dec 31, 2025 576.56 Mn
Sep 30, 2025 373.62 Mn
Jun 30, 2025 332.58 Mn
Mar 31, 2025 235.67 Mn
Dec 31, 2024 284.59 Mn
Sep 30, 2024 300.29 Mn
Jun 30, 2024 319.05 Mn
Mar 31, 2024 274.09 Mn
Dec 31, 2023 272.73 Mn
Sep 30, 2023 241.10 Mn
Jun 30, 2023 109.48 Mn
Mar 31, 2023 68.49 Mn
Dec 31, 2022 49.06 Mn
Sep 30, 2022 11.01 Mn
Jun 30, 2022 51.65 Mn
Mar 31, 2022 11.02 Mn
Dec 31, 2021 266.11 Mn
Sep 30, 2021 5.23 Mn
Jun 30, 2021 5.21 Mn